Sonelokimab
Also known as: ALX-0761, M1095, Sonelokimab
Source Sonelokimab at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Sonelokimab is a bispecific trivalent nanobody targeting IL‑17 cytokines, under clinical development for severe asthma, COPD, and other inflammatory diseases.
Mechanism of Action
Trivalent single-domain antibody that binds IL‑17A, IL‑17F and IL‑17A/F heterodimer, blocking IL‑17 signaling and downstream inflammatory pathways.
Routes of Administration
Goals & Uses
- Severe asthmaRespiratoryModerate
- Chronic obstructive pulmonary disease (COPD)RespiratoryModerate
- Inhibition of IL-17A and IL-17F signalingImmunology / Cytokine BlockadeHigh
- Reduction of plaque psoriasis severityDermatology / Anti InflammatoryHigh
- Treatment of psoriatic arthritisRheumatologyLow
Contraindications
- Active serious infections (e.g., active tuberculosis)InfectionHigh
- Known hypersensitivity to sonelokimab or nanobody componentsAllergy / ImmunologyHigh
- Hypersensitivity to sonelokimab or any excipientAllergyHigh
- Active inflammatory bowel diseaseGastroenterologyModerate
Adverse Effects
- Hypersensitivity reactionsImmunologicUncommon
- Candidiasis (mucocutaneous)InfectionsUncommon
- Injection site reactionsLocalCommon
- NasopharyngitisInfectiousCommon
- Upper respiratory tract infectionInfectiousCommon
- Inflammatory bowel disease exacerbation or new onsetGastrointestinalRare
- Upper respiratory tract infectionsInfectious DiseaseCommon
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
Drug Interactions
- Live vaccinesHigh
- Immunosuppressants (e.g., systemic corticosteroids)Moderate
- Other immunosuppressants (e.g., methotrexate, cyclosporine)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Patients with latent tuberculosisInfectious DiseaseRelative
- Pediatric patients <12 yearsAgeAbsolute
Regulatory Status
- European UnionInvestigationalClinical trials ongoing; not yet authorized.
- United StatesInvestigationalIND in place; Phase 2/3 trials ongoing.
- United KingdomInvestigationalUnder MHRA review; trials in progress.
As of the knowledge cutoff, sonelokimab has not received regulatory approval in any major jurisdiction. Phase 3 trials (MATURA program) were ongoing or reporting results for plaque psoriasis. No FDA, EMA, or MHRA approval granted.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Sonelokimab?
Sonelokimab is a bispecific trivalent nanobody targeting IL‑17 cytokines, under clinical development for severe asthma, COPD, and other inflammatory diseases.
What is Sonelokimab used for?
Sonelokimab is educationally associated with: Severe asthma, Chronic obstructive pulmonary disease (COPD), Inhibition of IL-17A and IL-17F signaling, Reduction of plaque psoriasis severity, Treatment of psoriatic arthritis. Educational only — not medical advice.
How is Sonelokimab administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Sonelokimab?
Reported adverse effects include: Hypersensitivity reactions, Candidiasis (mucocutaneous), Injection site reactions, Nasopharyngitis, Upper respiratory tract infection, Inflammatory bowel disease exacerbation or new onset, Upper respiratory tract infections, Injection site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Sonelokimab?
Recorded contraindications: Active serious infections (e.g., active tuberculosis), Known hypersensitivity to sonelokimab or nanobody components, Hypersensitivity to sonelokimab or any excipient, Active inflammatory bowel disease. Consult a qualified clinician before use.